These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 16339687)

  • 1. Physiology and pathophysiology of iron cardiomyopathy in thalassemia.
    Wood JC; Enriquez C; Ghugre N; Otto-Duessel M; Aguilar M; Nelson MD; Moats R; Coates TD
    Ann N Y Acad Sci; 2005; 1054():386-95. PubMed ID: 16339687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of magnetic resonance imaging estimation of myocardial iron to left ventricular systolic and diastolic function in thalassemia.
    Leonardi B; Margossian R; Colan SD; Powell AJ
    JACC Cardiovasc Imaging; 2008 Sep; 1(5):572-8. PubMed ID: 19356483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T2* magnetic resonance and myocardial iron in thalassemia.
    Pennell DJ
    Ann N Y Acad Sci; 2005; 1054():373-8. PubMed ID: 16339685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):219-27. PubMed ID: 16798647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron and oxidative stress in cardiomyopathy in thalassemia.
    Berdoukas V; Coates TD; Cabantchik ZI
    Free Radic Biol Med; 2015 Nov; 88(Pt A):3-9. PubMed ID: 26216855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron Chelation Therapy as a Modality of Management.
    Aydinok Y
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):261-275. PubMed ID: 29458731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
    Peng CT; Tsai CH; Wu KH
    Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
    Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
    Vlachaki E; Agapidou A; Spanos G; Klonizakis P; Vetsiou E; Mavroudi M; Boura P
    Hemoglobin; 2015; 39(5):299-304. PubMed ID: 26177199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI monitoring of myocardial iron overload: use of cardiac MRI combined with hepatic MRI in a cohort of multi-transfused patients with thalassaemia.
    Quatre A; Jacquier A; Petit P; Giorgi R; Thuret I
    Diagn Interv Imaging; 2014 Nov; 95(11):1065-9. PubMed ID: 25001363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and treatment of cardiac iron overload in transfusion-dependent thalassemia patients.
    Siri-Angkul N; Chattipakorn SC; Chattipakorn N
    Expert Rev Hematol; 2018 Jun; 11(6):471-479. PubMed ID: 29754517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac complications in beta-thalassemia: From mice to men.
    Kumfu S; Fucharoen S; Chattipakorn SC; Chattipakorn N
    Exp Biol Med (Maywood); 2017 Jun; 242(11):1126-1135. PubMed ID: 28485683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI and iron-overload cardiomyopathy in thalassaemia.
    Pennell D
    Circulation; 2006 Mar; 113(11):f43-4. PubMed ID: 16552847
    [No Abstract]   [Full Text] [Related]  

  • 14. Mechanisms of and obstacles to iron cardiomyopathy in thalassemia.
    Peng CT; Chang JS; Wu KH; Tsai CH; Lin HS
    Front Biosci; 2008 May; 13():5975-87. PubMed ID: 18508636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalassemia.
    Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
    Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart Rate Variability for Early Detection of Iron Overload Cardiomyopathy in β-Thalassemia Patients.
    Koonrungsesomboon N; Tantiworawit A; Phrommintikul A; Saekho S; Srichairattanakool S; Chattipakorn N
    Hemoglobin; 2015; 39(4):281-6. PubMed ID: 26029793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.
    Taher AT; Musallam KM; Viprakasit V; Porter JB; Cappellini MD
    Blood Cells Mol Dis; 2014; 52(2-3):88-90. PubMed ID: 24041597
    [No Abstract]   [Full Text] [Related]  

  • 18. Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with beta-thalassemia major.
    Wu KH; Chang JG; Ho YJ; Wu SF; Peng CT
    Hemoglobin; 2006; 30(2):251-6. PubMed ID: 16798650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global longitudinal strain as an Indicator of cardiac Iron overload in thalassemia patients.
    Abtahi F; Abdi A; Jamshidi S; Karimi M; Babaei-Beigi MA; Attar A
    Cardiovasc Ultrasound; 2019 Nov; 17(1):24. PubMed ID: 31684963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.